Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.
Cogent Biosciences has raised $200.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in November 2025.
Cogent Biosciences's investors include Novo Holdings, TCG Crossover, Wellington Management, Adage Capital Management, Perceptive Advisors.
Cogent Biosciences is headquartered in Waltham, United States.
Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.
Cogent Biosciences is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cogent Biosciences — Funding & Investors." VCBacked, November 10, 2025, https://www.vcbacked.co/company/cogent-biosciences. Accessed October 31, 2026.
VCBacked. (2025). Cogent Biosciences — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/cogent-biosciences
{{cite web |title=Cogent Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/cogent-biosciences |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated